Close Menu

NEW YORK (GenomeWeb) – Adding its name to a growing list, Chinese firm SeekIn is eyeing a new funding round to support clinical validation and commercialization of a DNA-based blood test for early cancer detection.

Similar to US firms Grail and Freenome, SeekIn is using machine learning to train classifiers that can pick up signals in circulating cell-free DNA (and potentially from other molecular information in the blood) that represent the faint signs of an unknown tumor in the body.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.